 Positive results were announced from the phase 2 NCI-led PDS0101 triple-combination study in patients with HPV16 cancers; both CPI naive and CPI refractory patients were helped. Positive results were also announced from the phase 2 study using PDS0101 Keytruda for recurrent or metastatic head and neck cancer patients. 